Trial Profile
Phase 1b/2, Multicenter, Open-label Study of Oprozomib and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Dexamethasone (Primary) ; Oprozomib (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions; Therapeutic Use
- Sponsors Amgen; Onyx Pharmaceuticals
- 16 Jul 2020 Trial design parallel was added, primary endpoint was added/
- 16 Jul 2020 The study was discontinued because enrollment halted during phase 2 to reformulate the investigational product.
- 22 Jun 2020 Status changed from completed to discontinued.